What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Khavinson immune / endocrine short-peptide bioregulator
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing Crystagen inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Crystagen is a Khavinson-class short-peptide bioregulator positioned within the Khavinson framework as the immune and endocrine regulatory peptide, targeting thymic and endocrine-tissue gene-expression programs under the shared hypothesis of tissue-specific bioregulator activity. Crystagen complements the larger and more rigorously characterized immune-modulation peptides in the catalog (Thymosin Alpha-1, Thymulin) by occupying the Khavinson short-peptide niche for buyers specifically studying the Khavinson framework's hypothesis rather than the broader thymic-peptide pharmacology. PeptideXpo supplies Crystagen as a lyophilized 20 mg vial at ≥99.0% HPLC purity. As with the rest of the Khavinson class, sequence verification on the batch COA is essential because CAS is not consistently registered and the family members differ in tissue-specific positioning rather than analytical fingerprint. Buyers working with Crystagen should confirm the sequence matches their reference protocol via COA at batch receipt.
Who buys this, and why
Custom-blend buyers are almost always OEM clients building a branded product around a specific ratio of two or more peptides. The development workflow is collaborative: ratio target, analytical method to verify it, stability protocol in the chosen carrier, and packaging selection are all defined in the OEM brief before the first commercial run. Sample-stage volumes are usually 5-10 g of finished blend; commercial MOQ depends on the components.
Primary buyer fit: academic and contract research laboratories.
Specifications
Documentation available on request
Regulatory note
Khavinson bioregulator; CAS commonly not registered. Confirm sequence and identity per batch COA.
Frequently asked questions
Crystagen and Thymosin Alpha-1 occupy different research niches despite overlapping marketed indications. Thymosin Alpha-1 is a defined 28-amino-acid peptide with extensive Western peer-reviewed clinical-trial data and approved-drug status in 35+ jurisdictions, it is the appropriate choice for research workflows that need to align with published Western clinical data and rigorous mechanism-of-action literature. Crystagen is a Khavinson-class short peptide with research evidence concentrated in Russian-language journals, appropriate for buyers specifically studying the Khavinson bioregulator framework or replicating Russian-school protocols. The two are not chemically equivalent or pharmacologically interchangeable; choose based on which evidence base your research is aligning with.
Khavinson-school publications on Crystagen focus on thymic and endocrine-tissue gene-expression effects in animal models of age-related immune decline, with reported readouts on T-cell maturation markers, lymphocyte proliferation responses, and antibody-response capacity in aged-rodent models. The mechanism hypothesis within the Khavinson framework is that Crystagen acts as an endogenous-mimetic bioregulator of thymic-tissue gene expression, supporting the thymic-output capacity that declines with age and contributing to age-related immunosenescence. As with the broader Khavinson framework, the mechanism details are hypothesized rather than independently confirmed at the rigor level of Western mechanism-of-action research.
All three products occupy the thymic-immune-modulation space but with substantially different characterization. Thymulin is a defined 9-amino-acid zinc-binding peptide (CAS 63958-90-7), the most chemically defined of the three. Thymalin is a complex multi-peptide extract derived from bovine thymus tissue, similar in compositional nature to Cerebrolysin, a multi-component preparation rather than a single molecule. Crystagen is a Khavinson-class short peptide positioned as the synthetic-simplified version of the thymic-tissue regulatory peptides. Buyers should be explicit at order placement about which they want, the three products are not chemically interchangeable, and the COA must specify which compositional class the released material represents.
Related peptides
Thymic immune-modulation peptide(s)
4-mer
Khavinson cortical bioregulator tetrapeptide (Ala-Glu-Asp-Pro, AEDP)
